GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes Mellitus
Open Access
- 2 February 2012
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 366 (5), 433-442
- https://doi.org/10.1056/nejmoa1107096
Abstract
The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with recent-onset type 1 diabetes. We studied 334 patients, 10 to 20 years of age, with type 1 diabetes, fasting C-peptide levels of more than 0.3 ng per milliliter (0.1 nmol per liter), and detectable serum GAD65 autoantibodies. Within 3 months after diagnosis, patients were randomly assigned to receive one of three study treatments: four doses of GAD-alum, two doses of GAD-alum followed by two doses of placebo, or four doses of placebo. The primary outcome was the change in the stimulated serum C-peptide level (after a mixed-meal tolerance test) between the baseline visit and the 15-month visit. Secondary outcomes included the glycated hemoglobin level, mean daily insulin dose, rate of hypoglycemia, and fasting and maximum stimulated C-peptide levels. The stimulated C-peptide level declined to a similar degree in all study groups, and the primary outcome at 15 months did not differ significantly between the combined active-drug groups and the placebo group (P=0.10). The use of GAD-alum as compared with placebo did not affect the insulin dose, glycated hemoglobin level, or hypoglycemia rate. Adverse events were infrequent and mild in the three groups, with no significant differences. Treatment with GAD-alum did not significantly reduce the loss of stimulated C peptide or improve clinical outcomes over a 15-month period. (Funded by Diamyd Medical and the Swedish Child Diabetes Foundation; ClinicalTrials.gov number, NCT00723411.)Keywords
This publication has 34 references indexed in Scilit:
- C-peptide and long-term complications of diabetesPediatric Diabetes, 2010
- β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications TrialDiabetes Care, 2003
- Type 1 diabetes: new perspectives on disease pathogenesis and treatmentThe Lancet, 2001
- Ketoacidosis in young adults is not related to the islet antibodies at the diagnosis of Type 1 diabetes mellitus – a nationwide studyDiabetic Medicine, 2000
- Effect of Intensive Therapy on Residual β-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications TrialAnnals of Internal Medicine, 1998
- Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual beta cell function. Childhood Diabetes in Finland Study Group.Archives of Disease in Childhood, 1996
- Declining Incidence of Nephropathy in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1994
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial GroupDiabetes, 1988
- Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes.BMJ, 1979